Compare Cytokinetics Inc (CYTK) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Prologis Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Prologis Inc trades at $129.52 (market cap $120.98B). The key difference: Prologis Inc is far larger — about 14.2× Cytokinetics Inc's market cap, and Prologis Inc pays a 3.36% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Prologis Inc for 102 Days on average.
| CYTK | PLD | |
|---|---|---|
Market Cap | $8.50B | $120.98B |
Volume | 2,395,556 | 3,604,776 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $149.96 |
52-Week Low | $54.76 | $111.23 |
Typical Hold Time | 19 Days | 102 Days |
Enterprise Value | $8.60B | $155.72B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Prologis (PLD) trades at $129.29, up 0.47% today, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Revenue grew to $8.79B in 2025, and net income margin stands strong at 45.79%. Recent news highlights strong leasing activity and data center growth potential, though the stock faces near-term resistance near $129.
The outlook for PLD is positive, supported by robust fundamentals and analyst consensus favoring a buy rating with a $155.15 price target. Key opportunities include e-commerce and data center demand driving rent growth. Risks involve rising debt levels, with debt-to-asset ratio increasing to 37.2% in 2025, and broader REIT sector volatility amid interest rate concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
